Literature DB >> 80608

Photodegradation of dacarbazine.

G M Baird, M L Willoughby.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 80608     DOI： 10.1016/s0140-6736(78)92794-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  [Antineoplastic drug-induced extravasation].

Authors:  Maike de Wit
Journal:  Med Klin (Munich)       Date:  2010-11

2.  Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: a double-blind randomized crossover study.

Authors:  Hiroki Nagai; Toshiyuki Kitano; Takafumi Nishimura; Hiroyasu Yasuda; Kazumi Nakata; Sachie Takashima; Masashi Kanai; Shigemi Matsumoto; Yukiko Mori; Yuichi Kakudo; Hiroyasu Sato; Takuhiro Yamaguchi; Kaoru Kameno; Young Hak Kim; Michiaki Mishima; Kazuhiro Yanagihara
Journal:  Support Care Cancer       Date:  2013-07-23       Impact factor: 3.603

3.  Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.

Authors:  P J Frosch; B M Czarnetzki; E Macher; E Grundmann; I Gottschalk
Journal:  J Cancer Res Clin Oncol       Date:  1979       Impact factor: 4.553

Review 4.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea (FIVB) in colon cancer.

Authors:  G Falkson; H C Falkson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Mechanisms of hepatotoxicity caused by dacarbazine in rats.

Authors:  R Paschke; M Heine; S Braun; K H Usadel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.

Authors:  N M Bleehen; A H Calvert; S M Lee; P Harper; S B Kaye; I Judson; M Brampton
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.